Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $34.75, for a total transaction of $278,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Tabula Rasa HealthCare Inc (NASDAQ TRHC) traded down $0.40 during mid-day trading on Thursday, reaching $34.35. 66,218 shares of the company traded hands, compared to its average volume of 204,877. The firm has a market capitalization of $624.89, a P/E ratio of -137.40, a P/E/G ratio of 3.65 and a beta of 3.93. Tabula Rasa HealthCare Inc has a 1-year low of $11.59 and a 1-year high of $38.23. The company has a quick ratio of 0.66, a current ratio of 0.73 and a debt-to-equity ratio of 0.47.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.06 earnings per share. sell-side analysts expect that Tabula Rasa HealthCare Inc will post 0.03 EPS for the current fiscal year.
Several brokerages have recently issued reports on TRHC. First Analysis began coverage on shares of Tabula Rasa HealthCare in a report on Wednesday, November 1st. They set an “overweight” rating and a $41.00 price target for the company. Piper Jaffray Companies reissued an “overweight” rating and set a $35.00 price target on shares of Tabula Rasa HealthCare in a report on Tuesday, November 7th. They noted that the move was a valuation call. William Blair began coverage on shares of Tabula Rasa HealthCare in a report on Monday, December 11th. They set an “outperform” rating for the company. BidaskClub downgraded shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $31.00 price target for the company in a report on Wednesday, October 11th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Tabula Rasa HealthCare has an average rating of “Buy” and an average price target of $29.78.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.